J Korean Med Sci.  2016 May;31(5):825-826. 10.3346/jkms.2016.31.5.825.

The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase

• Lee J
• Sinn DH
• Paik SW

• KMID: 2373687
• DOI: http://doi.org/10.3346/jkms.2016.31.5.825

Abstract

No abstract available.

MeSH Terms

*Alanine Transaminase
Antiviral Agents/therapeutic use
Humans
*Liver Cirrhosis
Antiviral Agents
Alanine Transaminase

Reference

1. Lee J, Sinn DH, Kim JH, Gwak GY, Kim HS, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, et al. Hepatocellular carcinoma risk of compensated cirrhosis patients with elevated HBV DNA Levels according to serum aminotransferase levels. J Korean Med Sci. 2015; 30:1618–1624.

2. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology. 2010; 51:1577–1583.

3. Korean Association for the Study of the Liver. KASL Clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2012; 18:109–162.

4. Keshvari M, Alavian SM, Sharafi H. How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon. 2014; 14:e15285.

5. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000; 342:1266–1271.

6. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63:261.

7. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167–185.

8. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012; 18:109–162.

9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661–662.

10. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009; 49:S185–S195.

11. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381:468–475.

12. Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014; 63:1943–1950.

13. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351:1521–1531.